Spyre Therapeutics Inc. – Filings and Transcripts

NASDAQ: SYRE
Share price (8/6/26): $103.42
Market cap (8/6/26): $9.119 billion

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 06/30/26 Q2

ended 03/31/26 Q1

ended 12/31/25 FY 2025

ended 09/30/25 Q3

ended 06/30/25 Q2

Prospectuses and Registrations Filter

Automatic shelf registration

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Updated info for already-effective prospectus

Registration of securities for employees

Ownership Filter

Albers Jeffrey W.

Albers Jeffrey W.

Burrows Scott L

Burrows Scott L

News Filter

Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Announces Potential Best-In-Class SPY002 (Anti-Tl1a) Part a Induction Results From SKYLINE Trial in Moderate-To-Severe Ulcerative Colitis Patients

Other Events, Financial Statements or Exhibits

Change in Directors, Officers or Compensation, Shareholder Vote Results, Financial Statements or Exhibits

Reports First Quarter 2026 Financial Results and Provides Corporate Update

Proxies Filter

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Definitive proxy

Definitive proxy

Other Filter

Scanned paper annual report submission

Notice of effectiveness

Notice of effectiveness

Correspondence with the SEC

Letter from the SEC